Optimal management of elderly patients with glioblastoma

Cancer Treatment Reviews

Volumn 39, Issue 4, 2013, Pages 350-357

  Laperriere, Normand ^a   Weller, Michael ^b   Stupp, Roger ^c   Perry, James R ^d   Brandes, Alba A ^e   Wick, Wolfgang ^f   van den Bent, Martin J ^g  

^a University of Toronto   (Canada)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e Azienda USL di Bologna   (Italy)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Elderly; Glioblastoma; Radiotherapy; Survival; Temozolomide

Indexed keywords

CARMUSTINE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; AGED; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CRANIOTOMY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLIOBLASTOMA; HEALTH CARE ORGANIZATION; HEMATOLOGIC DISEASE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; METHYLATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; PROMOTER REGION; REVIEW; SIDE EFFECT; STEREOTACTIC BIOPSY; THROMBOCYTOPENIA; UROSEPSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875502202     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.008     Document Type: Review

References (61)

1. Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259-273.
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Iwamoto F.M., Reiner A.S., Panageas K.S., Elkin E.B., Abrey L.E. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008, 64:628-634.
5. Kita D., Ciernik I.F., Vaccarella S., et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 2009, 33:17-22.
6. Paszat L., Laperriere N., Groome P., Schulze K., Mackillop W., Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:100-107.
7. Laperriere N, O'Callaghan C, Ding K, et al. Rationale and design for a phase III randomized controlled trial in elderly patients with glioblastoma multiforme: NCIC CTG CE. Paper presented at: 13th Biennial Canadian Neuro-Oncology Meeting 16-18 May, 2008; Banff, Alberta, Canada.
8. Balducci L., Colloca G., Cesari M., Gambassi G. Assessment and treatment of elderly patients with cancer. Surg Oncol 2010, 19:117-123.
9. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
10. Wheatley-Price P., Ding K., Seymour L., Clark G.M., Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:2350-2357.
11. Lawrence Y.R., Li X.A., El Naqa I., et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010, 76:S20-S27.
12. Ruben J.D., Dally M., Bailey M., Smith R., McLean C.A., Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499-508.
13. Lawrence Y.R., Wang M., Dicker A.P., et al. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer 2011, 104:1365-1371.
14. Barnholtz-Sloan J.S., Williams V.L., Maldonado J.L., et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008, 108:642-648.
15. Hess K.R., Broglio K.R., Bondy M.L. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004, 101:2293-2299.
16. Central Brain Tumor Registry of the United States. 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in Eighteen States in 2002-2006 December 2009.
17. US Census Bureau. Census of Population and Housing 1980 Census. Available at. Accessed 13 October, 2011. http://www.census.gov/prod/www/abs/decennial/1980cenpopv1.html.
18. US Census Bureau. National Population Projections. Available at. Accessed 13 October, 2011. http://www.census.gov/population/www/projections/2008projections.html.
19. Fried L.P., Hall W.J. Editorial: leading on behalf of an aging society. J Am Geriatr Soc 2008, 56:1791-1795.
20. Lowry J.K., Snyder J.J., Lowry P.W. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998, 55:922-928.
21. Sijben A.E., McIntyre J.B., Roldan G.B., et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008, 89:97-103.
22. Minniti G., De Sanctis V., Muni R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008, 88:97-103.
23. Minniti G., De Sanctis V., Muni R., et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 2009, 91:95-100.
24. Gerstner E.R., Yip S., Wang D.L., Louis D.N., Iafrate A.J., Batchelor T.T. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009, 73:1509-1510.
25. Iwamoto F.M., Cooper A.R., Reiner A.S., Nayak L., Abrey L.E. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer 2009, 115:3758-3766.
26. Vuorinen V., Hinkka S., Farkkila M., Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003, 145:5-10.
27. Scott J., Tsai Y.Y., Chinnaiyan P., Yu H.H. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2011, 81:206-210.
28. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
29. Lamborn K.R., Chang S.M., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004, 6:227-235.
30. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
31. Piccirilli M., Bistazzoni S., Gagliardi F.M., et al. Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori 2006, 92:98-103.
32. Brandes A.A., Franceschi E., Tosoni A., et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009, 115:3512-3518.
33. Minniti G., Salvati M., Arcella A., et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011, 102:311-316.
34. Weller M, Hentschel B, Felsberg J, et al. Impact of MGMT promoter methylation in glioblastoma of the elderly. J Clin Oncol. 2011;29 (Suppl.):Abstract 2001.
35. von Deimling A., Korshunov A., Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21:74-87.
36. Hartmann C., Hentschel B., Wick W., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120:707-718.
37. Chaichana K.L., Garzon-Muvdi T., Parker S., et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 2011, 18:239-245.
38. Chaichana K.L., Chaichana K.K., Olivi A., et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011, 114:587-594.
39. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535.
40. Bauman G.S., Gaspar L.E., Fisher B.J., Halperin E.C., Macdonald D.R., Cairncross J.G. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994, 29:835-839.
41. Hoegler D.B., Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 1997, 33:201-204.
42. Meckling S., Dold O., Forsyth P.A., Brasher P., Hagen N.A. Malignant supratentorial glioma in the elderly: is radiotherapy useful?. Neurology 1996, 47:901-905.
43. Thomas R., James N., Guerrero D., Ashley S., Gregor A., Brada M. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 1994, 33:113-116.
44. Ford J.M., Stenning S.P., Boote D.J., et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 1997, 9:20-24.
45. Jeremic B., Shibamoto Y., Grujicic D., et al. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. J Neurooncol 1999, 44:85-90.
46. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
47. Lai R., Hershman D.L., Doan T., Neugut A.I. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 2010, 12:190-198.
48. Scott J.G., Suh J.H., Elson P., et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 2011, 13:428-436.
49. Brandes A.A., Vastola F., Basso U., et al. A prospective study on glioblastoma in the elderly. Cancer 2003, 97:657-662.
50. Combs S.E., Wagner J., Bischof M., et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008, 70:987-992.
51. Fiorica F., Berretta M., Colosimo C., et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010, 51:31-35.
52. Kimple R.J., Grabowski S., Papez M., Collichio F., Ewend M.G., Morris D.E. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?. Am J Clin Oncol 2010, 33:265-270.
53. Glantz M., Chamberlain M., Liu Q., Litofsky N.S., Recht L.D. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262-2266.
54. Chinot O.L., Barrie M., Frauger E., et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208-2214.
55. Chamberlain M.C., Chalmers L. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol 2007, 82:207-209.
56. Laigle-Donadey F., Figarella-Branger D., Chinot O., et al. Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 2010, 99:89-94.
57. Gállego Pérez-Larraya J., Ducray F., Chinot O., et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011, 29:3050-3055.
58. Wick W, Engel C, Combs SE, et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010;28:Abstract LBA2001.
59. Malmstrom A, Gronberg BH, Stupp R, et al. Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), J Clin Oncol. 2010;28:Abstract LBA2002.
60. Weller M., Stupp R., Reifenberger G., et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 2010, 6:39-51.
61. Weller M., Felsberg J., Hartmann C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743-5750.